Verification evidence is still being completed.
PDF / print export
Acesion Pharma
Copenhagen, Denmark
- Verified lead
- Anders Haahr Mathiesen
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Cardiovascular Therapeutics, Atrial Fibrillation, Arrhythmia, Clinical Development, and Biotech
- Review cycle
- May 2026
- Full address
- Ole Maaloes Vej 3, 2200 Copenhagen N, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Acesion Pharma contact page confirming the Copenhagen address.
- Editorial note
- Acesion Pharma is published because official company materials confirm current leadership, Copenhagen operating address, and a real cardiovascular therapeutics platform.
Cardiovascular Therapeutics, Atrial Fibrillation, Arrhythmia, Clinical Development, and Biotech
Official leadership disclosure, Official Copenhagen address disclosure, Clinical-stage therapeutics platform claim
Acesion Pharma is published because official company materials confirm current leadership, Copenhagen operating address, and a real cardiovascular therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Copenhagen, Denmark
Acesion Pharma
Cardiovascular Therapeutics, Atrial Fibrillation, Arrhythmia, Clinical Development, and Biotech · Clinical-stage therapeutics platform
Verified 22 Mar 2026 · 2 sources
Clinical
Acesion Pharma runs cardiac drug development, clinical therapeutics programs, and cardiovascular platform development in Copenhagen, Denmark.
Contact & location
- Website
- acesionpharma.com
- Company page
- Lead
- Anders Haahr Mathiesen (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 22 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Cardiac Drug Development · Clinical Therapeutics Programs · Cardiovascular Platform Development
- Founded
- 2013
- Headcount
- 11-50
Clinical profileSTATUS: VERIFIED MARCH 2026
Anders Haahr Mathiesen
Chief Executive Officer
Full addressOle Maaloes Vej 3, 2200 Copenhagen N, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Clinical-stage therapeutics platform
Copenhagen, Denmark. Cardiovascular Therapeutics, Atrial Fibrillation, Arrhythmia, Clinical Development, and Biotech. Review completed on 22 Mar 2026.
Danish corporate and clinical-development oversight
Official leadership disclosure, Official Copenhagen address disclosure, Clinical-stage therapeutics platform claim
Cardiovascular Therapeutics, Atrial Fibrillation, Arrhythmia, Clinical Development, and Biotech
Acesion Pharma is published because official company materials confirm current leadership, Copenhagen operating address, and a real cardiovascular therapeutics platform.
Editorial note
Acesion Pharma is published because official company materials confirm current leadership, Copenhagen operating address, and a real cardiovascular therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Cardiac Drug Development
Clinical Therapeutics Programs
Cardiovascular Platform Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Cardiovascular development workflow
Clinical program systems
Therapeutics R&D infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Acesion Pharma located?
- Acesion Pharma operates from Ole Maaloes Vej 3, 2200 Copenhagen N, Denmark, Copenhagen, Denmark.
- Who runs Acesion Pharma?
- Acesion Pharma is led by Anders Haahr Mathiesen, Chief Executive Officer. Verified 22 Mar 2026.
- What does Acesion Pharma do?
- Acesion Pharma runs cardiac drug development, clinical therapeutics programs, and cardiovascular platform development in Copenhagen, Denmark. Core capabilities: Cardiac Drug Development, Clinical Therapeutics Programs, Cardiovascular Platform Development.
Editorial context
Related technical briefs
Briefs that name Copenhagen as a covered market or city.